title: Risk of venous thrombosis in patients with pancreatic adenocarcinoma.
abstract: OBJECTIVE
  To estimate the risk of venous thrombosis associated with pancreatic adenocarcinoma and its consequences on treatment and survival.
  
  
  METHODS
  We retrospectively analyzed a cohort of 90 patients (49 males, 41 females - median age: 67 years [range: 37-94]). Pancreatic adenocarcinoma was histologically proved in 72 patients (81%) and was metastatic in 49 patients (54.4%). A venous thrombosis was observed in 24 patients (26.7%). A pulmonary embolism occurred in 4 patients with 2 deaths. The risk of venous thrombosis was significantly reduced by the use of anti-thrombotic prophylaxis (HR: 0.03 [95CI: 0.003-0.27]) and increased among patients with a biological inflammatory syndrome (HR: 9.0 [95CI: 2.30-34.4]) and metastatic disease (HR: 4.4 [95CI: 1.1-17.9]). Overall survival was not different between patients with (6.6 months) or without (6.1 months) venous thrombosis.
  
  
  CONCLUSIONS
  The risk of venous thrombosis is important and may delay the treatment in patients with advanced pancreatic carcinoma. Some patients with high risk of venous thrombosis may benefit from a prophylactic anticoagulant treatment.
authors.affiliation: Service d'hépatogastroentérologie et oncologie digestive; Hôpital Ambroise-Paré, APHP. Boulogne.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Mitry
authors.forename: Raffic
authors.initials: R
authors.lastname: Taleb-Fayad
authors.forename: Antoine
authors.initials: A
authors.lastname: Deschamps
authors.forename: Nicolas
authors.initials: N
authors.lastname: Mansencal
authors.forename: Céline
authors.initials: C
authors.lastname: Lepère
authors.forename: Gilles
authors.initials: G
authors.lastname: Declety
authors.forename: Astrid
authors.initials: A
authors.lastname: Lièvre
authors.forename: Jean-Nicolas
authors.initials: JN
authors.lastname: Vaillant
authors.forename: Gilles
authors.initials: G
authors.lastname: Lesur
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Cramer
authors.forename: Olivier
authors.initials: O
authors.lastname: Dubourg
authors.forename: Philippe
authors.initials: P
authors.lastname: Rougier
mesh_terms: D000230:Adenocarcinoma / Q000150:complications* / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D002408:Catheters, Indwelling; D002423:Cause of Death; D015331:Cohort Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000150:complications*; D011655:Pulmonary Embolism / Q000209:etiology; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D020246:Venous Thrombosis / Q000209:etiology* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight